Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd-R Burmester

Showing results (161-170 of 293) with videos related to

Pageof 30
Sort By:
International Journal of Molecular Sciences|August 9, 2018
CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal CellsTimo Gaber, Kerstin Schönbeck, Holger Hoff, et al.
EULAR Rheumatology Open|June 29, 2026
Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover studyTomoko Hasunuma, Paul Emery, Ernest Choy, et al.
Annals of the Rheumatic Diseases|March 6, 2012
Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technologyStephanie G Werner, Hans-Eckhard Langer, Sarah Ohrndorf, et al.
Annals of the Rheumatic Diseases|November 19, 2016
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trialGerd R Burmester, Yong Lin, Rahul Patel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2016
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor InhibitorsRoy Fleischmann, Janet van Adelsberg, Yong Lin, et al.
Annals of the Rheumatic Diseases|February 12, 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritisCharles Peterfy, Gerd R Burmester, Vivian P Bykerk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2004
Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cellsGabriela Riemekasten, Dirk Langnickel, Philipp Enghard, et al.
RMD Open|September 29, 2017
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumabGerd R Burmester, Gurjit S Kaeley, Arthur F Kavanaugh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateMark C Genovese, Josef S Smolen, Michael E Weinblatt, et al.
RMD Open|August 13, 2021
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, et al.
Pageof 30

Showing results (161-170 of 293) with videos related to

Sort By:
Pageof 30
International Journal of Molecular Sciences|August 9, 2018
CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal CellsTimo Gaber, Kerstin Schönbeck, Holger Hoff, et al.
EULAR Rheumatology Open|June 29, 2026
Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover studyTomoko Hasunuma, Paul Emery, Ernest Choy, et al.
Annals of the Rheumatic Diseases|March 6, 2012
Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technologyStephanie G Werner, Hans-Eckhard Langer, Sarah Ohrndorf, et al.
Annals of the Rheumatic Diseases|November 19, 2016
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trialGerd R Burmester, Yong Lin, Rahul Patel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2016
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor InhibitorsRoy Fleischmann, Janet van Adelsberg, Yong Lin, et al.
Annals of the Rheumatic Diseases|February 12, 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritisCharles Peterfy, Gerd R Burmester, Vivian P Bykerk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2004
Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cellsGabriela Riemekasten, Dirk Langnickel, Philipp Enghard, et al.
RMD Open|September 29, 2017
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumabGerd R Burmester, Gurjit S Kaeley, Arthur F Kavanaugh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateMark C Genovese, Josef S Smolen, Michael E Weinblatt, et al.
RMD Open|August 13, 2021
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, et al.
Pageof 30